|
TWI324604B
(en)
|
2003-06-18 |
2010-05-11 |
Novartis Ag |
New use of staurosporine derivatives
|
|
WO2005011598A2
(en)
*
|
2003-07-31 |
2005-02-10 |
University Of South Florida |
Leukemia treatment method and composition
|
|
CA2533861A1
(en)
*
|
2003-08-08 |
2005-02-17 |
Novartis Ag |
Combinations comprising staurosporines
|
|
JP2007523827A
(ja)
|
2003-08-25 |
2007-08-23 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
混合性白血病遺伝子の再構成を伴う急性リンパ芽球性白血病の処置方法
|
|
US7750160B2
(en)
|
2003-11-13 |
2010-07-06 |
Ambit Biosciences Corporation |
Isoxazolyl urea derivatives as kinase modulators
|
|
WO2005053704A1
(en)
*
|
2003-12-01 |
2005-06-16 |
Novartis Ag |
Method for predicting drug responsiveness in myeloid neoplasms
|
|
WO2005058341A2
(en)
*
|
2003-12-11 |
2005-06-30 |
Theravance, Inc. |
Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
|
CN101022799A
(zh)
*
|
2004-07-19 |
2007-08-22 |
约翰·霍普金斯大学 |
供免疫抑制的flt3抑制剂
|
|
GB0419159D0
(en)
*
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
|
JP2008520612A
(ja)
*
|
2004-11-24 |
2008-06-19 |
ノバルティス アクチエンゲゼルシャフト |
JAK阻害剤およびBcr−Abl、Flt−3、FAKまたはRAFキナーゼ阻害剤のうち少なくとも1個の組合せ
|
|
GB0426821D0
(en)
*
|
2004-12-07 |
2005-01-12 |
Novartis Ag |
Organic compounds
|
|
WO2006122150A1
(en)
|
2005-05-10 |
2006-11-16 |
Incyte Corporation |
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
|
US8071768B2
(en)
|
2005-06-10 |
2011-12-06 |
Janssen Pharmaceutica, N.V. |
Alkylquinoline and alkylquinazoline kinase modulators
|
|
US7825244B2
(en)
|
2005-06-10 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
|
|
BRPI0613868A2
(pt)
*
|
2005-07-20 |
2011-02-15 |
Novartis Ag |
compostos orgánicos
|
|
EP1926735A1
(en)
|
2005-09-22 |
2008-06-04 |
Incyte Corporation |
Tetracyclic inhibitors of janus kinases
|
|
JP2009511628A
(ja)
|
2005-10-18 |
2009-03-19 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Flt3キナーゼの阻害方法
|
|
GB0522932D0
(en)
*
|
2005-11-10 |
2005-12-21 |
Univ Southampton |
PKC412 in treatment of atypical chronic myeloid leukemia
|
|
KR20080067654A
(ko)
*
|
2005-11-14 |
2008-07-21 |
유니베르시태트 취리히 |
폐포성 횡문근육종에서 사용하기 위한 스타우로스포린유도체
|
|
PT1966202E
(pt)
|
2005-12-13 |
2012-01-03 |
Incyte Corp |
Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
|
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
|
SI2021335T1
(sl)
|
2006-04-20 |
2011-09-30 |
Janssen Pharmaceutica Nv |
Heterocikliäśne spojine kot zaviralci c-fms kinaze
|
|
WO2007124322A1
(en)
|
2006-04-20 |
2007-11-01 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
|
GB0612542D0
(en)
*
|
2006-06-23 |
2006-08-02 |
Novartis Ag |
Combinations comprising staurosporines
|
|
EP2121692B1
(en)
|
2006-12-22 |
2013-04-10 |
Incyte Corporation |
Substituted heterocycles as janus kinase inhibitors
|
|
RS53245B2
(sr)
|
2007-06-13 |
2022-10-31 |
Incyte Holdings Corp |
Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
|
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
|
WO2009064835A1
(en)
|
2007-11-16 |
2009-05-22 |
Incyte Corporation |
4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
|
|
BRPI0909040B8
(pt)
|
2008-03-11 |
2021-05-25 |
Incyte Holdings Corp |
derivados de azetidina e ciclobutano, seus usos, e composição
|
|
EP2274288A2
(en)
|
2008-04-24 |
2011-01-19 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
|
MX2011000235A
(es)
|
2008-07-08 |
2011-02-23 |
Incyte Corp |
1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa.
|
|
CL2009001884A1
(es)
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
US8765727B2
(en)
|
2009-01-23 |
2014-07-01 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
|
TW201100429A
(en)
|
2009-05-22 |
2011-01-01 |
Incyte Corp |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
PL2432472T3
(pl)
|
2009-05-22 |
2020-03-31 |
Incyte Holdings Corporation |
3-[4-(7H-Pirolo[2,3-d]pirymidyn-4-ylo)-1H-pirazol-1-ilo]oktano- lub heptano-nitryle jako inhibitory JAK
|
|
ME01838B
(me)
|
2009-06-29 |
2014-12-20 |
Lncyte Holdings Corp |
Pirimidinoni kao inhibitori pi3k
|
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
ES2435491T3
(es)
|
2009-10-09 |
2013-12-19 |
Incyte Corporation |
Derivados de hidroxilo, ceto y glucurónido de 3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
|
|
EP2327706A1
(en)
*
|
2009-11-30 |
2011-06-01 |
Novartis AG |
Polymorphous forms III and IV of N-benzoyl-staurosporine
|
|
US8759359B2
(en)
|
2009-12-18 |
2014-06-24 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as PI3K inhibitors
|
|
TW201130842A
(en)
|
2009-12-18 |
2011-09-16 |
Incyte Corp |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
|
WO2011083124A1
(en)
|
2010-01-05 |
2011-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Flt3 receptor antagonists for the treatment or the prevention of pain disorders
|
|
ES2539170T3
(es)
|
2010-01-12 |
2015-06-26 |
Ab Science |
Inhibidores de quinasas de oxazol
|
|
CN102844317B
(zh)
|
2010-02-18 |
2015-06-03 |
因西特公司 |
作为Janus激酶抑制剂的环丁烷和甲基环丁烷衍生物
|
|
MX354212B
(es)
|
2010-03-10 |
2018-02-19 |
Incyte Corp |
Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
|
|
CA2796311A1
(en)
|
2010-04-14 |
2011-10-20 |
Incyte Corporation |
Fused derivatives as pi3k.delta. inhibitors
|
|
EA202091303A3
(ru)
|
2010-05-21 |
2021-05-31 |
Инсайт Холдингс Корпорейшн |
Композиция ингибитора jak для местного применения
|
|
WO2011163195A1
(en)
|
2010-06-21 |
2011-12-29 |
Incyte Corporation |
Fused pyrrole derivatives as pi3k inhibitors
|
|
WO2012068440A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
|
CA2818542A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
JP5961187B2
(ja)
|
2010-12-20 |
2016-08-02 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン
|
|
EP2675451B9
(en)
|
2011-02-18 |
2017-07-26 |
Novartis Pharma AG |
mTOR/JAK INHIBITOR COMBINATION THERAPY
|
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
|
US9126948B2
(en)
|
2011-03-25 |
2015-09-08 |
Incyte Holdings Corporation |
Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
|
|
CN103797010B
(zh)
|
2011-06-20 |
2016-02-24 |
因塞特控股公司 |
作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
|
|
HK1198579A1
(en)
|
2011-08-10 |
2015-04-30 |
Novartis Pharma Ag |
Jak p13k/mtor combination therapy
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
|
SI3513793T1
(sl)
|
2011-09-02 |
2021-07-30 |
Incyte Holdings Corporation |
Heterociklilamini kot zaviralci PI3K
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
|
WO2013163228A1
(en)
*
|
2012-04-24 |
2013-10-31 |
International Stem Cell Corporation |
Derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells
|
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
|
SI2861595T1
(sl)
|
2012-06-13 |
2017-04-26 |
Incyte Holdings Corporation |
Substituirane triciklične spojine kot inhibitorji fgfr
|
|
ES2608628T3
(es)
|
2012-08-07 |
2017-04-12 |
Janssen Pharmaceutica Nv |
Procedimiento para la preparacion de derivados de ester heterociclicos
|
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
|
KR101738063B1
(ko)
|
2012-09-21 |
2017-05-19 |
아로그 파마슈티칼스, 인코퍼레이티드 |
구조적으로 활성인 인산화된 flt3 키나제의 억제 방법
|
|
BR112015009942A2
(pt)
|
2012-11-01 |
2017-07-11 |
Incyte Corp |
derivados de tiofeno fundidos tricíclicos como inibidores de jak
|
|
NZ708157A
(en)
|
2012-11-15 |
2019-07-26 |
Incyte Holdings Corp |
Sustained-release dosage forms of ruxolitinib
|
|
BR112015016282A2
(pt)
|
2013-01-07 |
2017-07-11 |
Arog Pharmaceuticals Inc |
crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
|
|
TWI687220B
(zh)
|
2013-03-01 |
2020-03-11 |
美商英塞特控股公司 |
吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
|
|
TWI634121B
(zh)
|
2013-03-06 |
2018-09-01 |
英塞特控股公司 |
用於製備jak抑制劑之方法及中間物
|
|
LT2986610T
(lt)
|
2013-04-19 |
2018-04-10 |
Incyte Holdings Corporation |
Bicikliniai heterociklai, kaip fgfr inhibitoriai
|
|
WO2014186706A1
(en)
|
2013-05-17 |
2014-11-20 |
Incyte Corporation |
Bipyrazole derivatives as jak inhibitors
|
|
MX394928B
(es)
|
2013-08-07 |
2025-03-24 |
Incyte Holdings Corp |
Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
|
|
CN105555313A
(zh)
|
2013-08-20 |
2016-05-04 |
因赛特公司 |
在c-反应蛋白水平较高的实体肿瘤患者中的存活益处
|
|
US10463658B2
(en)
|
2013-10-25 |
2019-11-05 |
Videra Pharmaceuticals, Llc |
Method of inhibiting FLT3 kinase
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
SG11201607083VA
(en)
|
2014-02-28 |
2016-09-29 |
Incyte Corp |
Jak1 inhibitors for the treatment of myelodysplastic syndromes
|
|
LT3116909T
(lt)
|
2014-03-14 |
2020-02-10 |
Novartis Ag |
Antikūno molekulės prieš lag-3 ir jų panaudojimas
|
|
HRP20201887T1
(hr)
|
2014-04-08 |
2021-02-05 |
Incyte Corporation |
LIJEČENJE B-STANIČNIH MALIGNITETA S KOMBINACIJOM INHIBITORA JAK i PI3K
|
|
SG11201609016VA
(en)
|
2014-04-30 |
2016-11-29 |
Incyte Corp |
Processes of preparing a jak1 inhibitor and new forms thereto
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
|
WO2015191677A1
(en)
|
2014-06-11 |
2015-12-17 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
|
|
US10065937B2
(en)
|
2014-07-31 |
2018-09-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
FLT3 receptor antagonists
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
EP3206711B1
(en)
|
2014-10-14 |
2023-05-31 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
US9586949B2
(en)
|
2015-02-09 |
2017-03-07 |
Incyte Corporation |
Aza-heteroaryl compounds as PI3K-gamma inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
SG10201913036RA
(en)
|
2015-02-20 |
2020-02-27 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
MA41607B1
(fr)
|
2015-02-27 |
2021-01-29 |
Incyte Corp |
Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
|
|
PE20171448A1
(es)
|
2015-03-10 |
2017-10-02 |
Aduro Biotech Inc |
Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
|
|
WO2016183062A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
|
|
US9732097B2
(en)
|
2015-05-11 |
2017-08-15 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
|
EP3317301B1
(en)
|
2015-07-29 |
2021-04-07 |
Novartis AG |
Combination therapies comprising antibody molecules to lag-3
|
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
CA3004138A1
(en)
|
2015-11-03 |
2017-05-11 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and tim-3 and their uses
|
|
AR106595A1
(es)
|
2015-11-06 |
2018-01-31 |
Incyte Corp |
COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
EP3792256B1
(en)
|
2016-01-05 |
2024-10-23 |
Incyte Corporation |
Pyridine compounds as pi3k-gamma inhibitors
|
|
CN110218206B
(zh)
*
|
2016-06-01 |
2022-03-04 |
中国海洋大学 |
双吲哚马来酰亚胺衍生物及其制备方法和用途
|
|
EP3254698A1
(en)
|
2016-06-08 |
2017-12-13 |
Universite De Montpellier |
Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
|
|
TW201803871A
(zh)
|
2016-06-24 |
2018-02-01 |
英塞特公司 |
作為PI3K-γ抑制劑之雜環化合物
|
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
AU2017353925A1
(en)
|
2016-11-02 |
2018-09-27 |
Arog Pharmaceuticals, Inc. |
Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
WO2018211018A1
(en)
|
2017-05-17 |
2018-11-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Flt3 inhibitors for improving pain treatments by opioids
|
|
WO2018217766A1
(en)
|
2017-05-22 |
2018-11-29 |
Whitehead Institute For Biomedical Research |
Kcc2 expression enhancing compounds and uses thereof
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
CN107417743B
(zh)
*
|
2017-06-15 |
2020-07-21 |
杭州科兴生物化工有限公司 |
星孢菌素醛基取代衍生物及其制备方法和应用
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
WO2019057649A1
(en)
|
2017-09-19 |
2019-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
|
|
MX2020003862A
(es)
|
2017-10-18 |
2020-08-13 |
Incyte Corp |
Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma).
|
|
AR113922A1
(es)
|
2017-12-08 |
2020-07-01 |
Incyte Corp |
Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
|
|
US11306079B2
(en)
|
2017-12-21 |
2022-04-19 |
Incyte Corporation |
3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
WO2019152374A1
(en)
|
2018-01-30 |
2019-08-08 |
Incyte Corporation |
Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
|
WO2019161098A1
(en)
|
2018-02-16 |
2019-08-22 |
Incyte Corporation |
Jak1 pathway inhibitors for the treatment of cytokine-related disorders
|
|
AU2019227607C1
(en)
|
2018-02-27 |
2023-07-20 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
|
|
WO2019226213A2
(en)
|
2018-03-08 |
2019-11-28 |
Incyte Corporation |
AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
|
|
US11584961B2
(en)
|
2018-03-30 |
2023-02-21 |
Incyte Corporation |
Biomarkers for inflammatory skin disease
|
|
HUE067471T2
(hu)
|
2018-03-30 |
2024-10-28 |
Incyte Corp |
Gennyes verejtékmirigy-gyulladás kezelése jak inhibitorok alkalmazásával
|
|
US11220510B2
(en)
|
2018-04-09 |
2022-01-11 |
Incyte Corporation |
Pyrrole tricyclic compounds as A2A / A2B inhibitors
|
|
PL3788047T3
(pl)
|
2018-05-04 |
2025-04-14 |
Incyte Corporation |
Stałe postacie inhibitora fgfr i sposoby ich otrzymywania
|
|
KR20210018264A
(ko)
|
2018-05-04 |
2021-02-17 |
인사이트 코포레이션 |
Fgfr 억제제의 염
|
|
MA52940A
(fr)
|
2018-05-18 |
2021-04-28 |
Incyte Corp |
Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
|
|
ES2929415T3
(es)
|
2018-05-25 |
2022-11-29 |
Incyte Corp |
Compuestos heterocíclicos tricíclicos como activadores de STING
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
BR112020024427A2
(pt)
|
2018-06-01 |
2021-03-23 |
Incyte Corporation |
regime de dosagem para o tratamento de distúrbios relacionados a pi3k
|
|
WO2020010003A1
(en)
|
2018-07-02 |
2020-01-09 |
Incyte Corporation |
AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
|
|
CA3105721A1
(en)
|
2018-07-05 |
2020-01-09 |
Incyte Corporation |
Fused pyrazine derivatives as a2a / a2b inhibitors
|
|
WO2020028565A1
(en)
|
2018-07-31 |
2020-02-06 |
Incyte Corporation |
Tricyclic heteraryl compounds as sting activators
|
|
US10875872B2
(en)
|
2018-07-31 |
2020-12-29 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
|
CR20250050A
(es)
|
2018-09-05 |
2025-03-19 |
Incyte Corp |
Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
CA3118324A1
(en)
|
2018-11-01 |
2020-05-07 |
Syros Pharmaceuticals, Inc. |
Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
WO2020102216A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Substituted heterocyclic derivatives as pi3k inhibitors
|
|
WO2020102150A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
|
US11078204B2
(en)
|
2018-11-13 |
2021-08-03 |
Incyte Corporation |
Heterocyclic derivatives as PI3K inhibitors
|
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
|
KR20210107069A
(ko)
|
2018-12-21 |
2021-08-31 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 컨쥬게이트와 키나아제 저해제의 조합
|
|
US12129267B2
(en)
|
2019-01-07 |
2024-10-29 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
|
EP3923949A1
(en)
|
2019-02-15 |
2021-12-22 |
Incyte Corporation |
Cyclin-dependent kinase 2 biomarkers and uses thereof
|
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
MA56215A
(fr)
|
2019-06-10 |
2022-04-20 |
Incyte Corp |
Traitement topique du vitiligo par un inhibiteur de jak
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
EP4007602A1
(en)
|
2019-08-01 |
2022-06-08 |
Incyte Corporation |
A dosing regimen for an ido inhibitor
|
|
PH12022550361A1
(en)
|
2019-08-14 |
2023-02-27 |
Incyte Corp |
Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
TW202115082A
(zh)
|
2019-08-26 |
2021-04-16 |
美商英塞特公司 |
作為a2a/a2b抑制劑之三唑并嘧啶
|
|
US11839619B2
(en)
|
2019-09-16 |
2023-12-12 |
The Regents Of The University Of California |
Methods for treatment of pediatric systemic mastocytosis
|
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
JP7693656B2
(ja)
|
2019-10-11 |
2025-06-17 |
インサイト・コーポレイション |
Cdk2阻害剤としての二環式アミン
|
|
CR20220169A
(es)
|
2019-10-14 |
2022-10-27 |
Incyte Corp |
Heterociclos bicíclicos como inhibidores de fgfr
|
|
US11992490B2
(en)
|
2019-10-16 |
2024-05-28 |
Incyte Corporation |
Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
|
|
JP7518900B2
(ja)
|
2019-10-16 |
2024-07-18 |
インサイト・コーポレイション |
皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
JP7720840B2
(ja)
|
2019-12-04 |
2025-08-08 |
インサイト・コーポレイション |
Fgfr阻害剤としての三環式複素環
|
|
AU2020395185A1
(en)
|
2019-12-04 |
2022-06-02 |
Incyte Corporation |
Derivatives of an FGFR inhibitor
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
AU2021230385A1
(en)
|
2020-03-06 |
2022-09-22 |
Incyte Corporation |
Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
|
|
PH12022552739A1
(en)
|
2020-04-16 |
2024-03-25 |
Incyte Corp |
Fused tricyclic kras inhibitors
|
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
|
JP2023528868A
(ja)
|
2020-06-02 |
2023-07-06 |
インサイト・コーポレイション |
Jak1阻害剤の調製プロセス
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
US11713310B2
(en)
|
2020-07-20 |
2023-08-01 |
Arog Pharmaceuticals, Inc. |
Crystal forms of crenolanib and methods of use thereof
|
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
|
US20230364095A1
(en)
|
2020-09-16 |
2023-11-16 |
Incyte Corporation |
Topical treatment of vitiligo
|
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
|
US11969420B2
(en)
|
2020-10-30 |
2024-04-30 |
Arog Pharmaceuticals, Inc. |
Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
|
|
WO2022090547A1
(en)
|
2020-10-30 |
2022-05-05 |
Dsm Ip Assets B.V. |
Production of carotenoids by fermentation
|
|
JP2023552452A
(ja)
|
2020-12-08 |
2023-12-15 |
インサイト・コーポレイション |
白斑治療用のjak1経路阻害薬
|
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
|
CN115124551B
(zh)
*
|
2021-03-24 |
2024-04-30 |
奥锐特药业(天津)有限公司 |
一种高纯度米哚妥林的制备方法
|
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含fgfr抑制劑及nectin-4靶向劑之組合療法
|
|
US12268667B2
(en)
|
2021-05-03 |
2025-04-08 |
Incyte Corporation |
JAK1 pathway inhibitors for the treatment of prurigo nodularis
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
EP4352060A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
WO2023283213A1
(en)
|
2021-07-07 |
2023-01-12 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
US20230114765A1
(en)
|
2021-07-14 |
2023-04-13 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
US12441742B2
(en)
|
2021-08-31 |
2025-10-14 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of KRAS
|
|
US12030883B2
(en)
|
2021-09-21 |
2024-07-09 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of KRAS
|
|
JP2024537824A
(ja)
|
2021-10-01 |
2024-10-16 |
インサイト・コーポレイション |
ピラゾロキノリンkras阻害剤
|
|
MX2024004444A
(es)
|
2021-10-14 |
2024-05-08 |
Incyte Corp |
Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
|
|
JP2024540411A
(ja)
|
2021-11-08 |
2024-10-31 |
プロジェントス・セラピューティクス・インコーポレイテッド |
血小板由来成長因子受容体(pdgfr)アルファ阻害剤及びその使用
|
|
US20230226040A1
(en)
|
2021-11-22 |
2023-07-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a kras inhibitor
|
|
TW202329937A
(zh)
|
2021-12-03 |
2023-08-01 |
美商英塞特公司 |
雙環胺ck12抑制劑
|
|
WO2023107705A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
US20230192722A1
(en)
|
2021-12-22 |
2023-06-22 |
Incyte Corporation |
Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
|
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
|
TW202341982A
(zh)
|
2021-12-24 |
2023-11-01 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Cdk2抑制劑及其用途
|
|
US20230279004A1
(en)
|
2022-03-07 |
2023-09-07 |
Incyte Corporation |
Solid forms, salts, and processes of preparation of a cdk2 inhibitor
|
|
EP4540252A1
(en)
|
2022-06-14 |
2025-04-23 |
Incyte Corporation |
Solid forms of a jak inhibitor and process of preparing the same
|
|
CN114853784B
(zh)
*
|
2022-06-16 |
2023-09-05 |
贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) |
一种十字孢碱类化合物及其制备方法与应用
|
|
US20250353842A1
(en)
|
2022-06-22 |
2025-11-20 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
|
WO2024015731A1
(en)
|
2022-07-11 |
2024-01-18 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
|
US20240058343A1
(en)
|
2022-08-05 |
2024-02-22 |
Incyte Corporation |
Treatment of urticaria using jak inhibitors
|
|
WO2024220532A1
(en)
|
2023-04-18 |
2024-10-24 |
Incyte Corporation |
Pyrrolidine kras inhibitors
|
|
US20240368156A1
(en)
|
2023-04-18 |
2024-11-07 |
Incyte Corporation |
2-azabicyclo[2.2.1]heptane kras inhibitors
|
|
WO2024254245A1
(en)
|
2023-06-09 |
2024-12-12 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
|
US20250163079A1
(en)
|
2023-11-01 |
2025-05-22 |
Incyte Corporation |
Kras inhibitors
|
|
WO2025129002A1
(en)
|
2023-12-13 |
2025-06-19 |
Incyte Corporation |
Bicyclooctane kras inhibitors
|